Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment

J Intensive Care Soc. 2019 May;20(2):174-181. doi: 10.1177/1751143718772789. Epub 2018 May 28.


We describe the use of Cytosorb™, a synthetic extracorporeal haemoperfusion adsorption column, in the management of two patients with drug induced cholestasis and a third with alcoholic hepatitis and subsequent acute on chronic liver failure. Cytosorb was used in these patients to remove bilirubin and bile acids by supporting impaired excretory hepatic function, alleviating symptoms with the intention of serving as a bridge to endogenous recovery. The first two cases demonstrate favourable biochemical and symptomatic responses; the third case demonstrated a good biochemical response but subsequently died from the complications of multiple organ failure. These cases suggest Cytosorb™ be evaluated as an adjunct to support liver excretory functions in other arenas, such as acute liver failure or overdose. It remains unclear whether extracorporeal therapies removing liver toxins allow faster or more complete spontaneous recovery of endogenous function.

Keywords: Cholestasis; Cytosorb; extra-corporeal; haemabsorption; haemoperfusion; liver failure; pruritis.

Publication types

  • Case Reports